SANTA CRUZ BIOTECHNOLOGY, INC.

GCN1L1 (L-15): sc-167966

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

GCN1L1 (GCN1 general control of amino-acid synthesis 1-like 1), also known as translational activator GCN1, is a 2,671 amino acid protein that is ubiquitously expressed and belongs to the GCN1 family. Functioning as a translation activator, GCN1L1 interacts with IMPACT to regulate GCN2 kinase activity. GCN1L1 contains 24 HEAT repeats and is encoded by a gene that maps to human chromosome 12q24.23. Chromosome 12 encodes over 1,100 genes and comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders.

REFERENCES

1. Nagase, T., Seki, N., Ishikawa, K., Ohira, M., Kawarabayasi, Y., Ohara, O., Tanaka, A., Kotani, H., Miyajima, N. and Nomura, N. 1996. Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain. DNA Res. 3: 321-329, 341.
2. Marton, M.J., Vazquez de Aldana, C.R., Qiu, H., Chakraburtty, K. and Hinnebusch, A.G. 1997. Evidence that GCN1 and GCN20, translational regulators of GCN4, function on elongating ribosomes in activation of eIF2alpha kinase GCN2. Mol. Cell. Biol. 17: 4474-4489.
3. Delgado Carrasco, J., Casanova Morcillo, A., Zabalza Alvillos, M. and Ayala Garces, A. 2001. Achondrogenesis type II-hypochondrogenesis: radiological features. An. Esp. Pediatr. 55: 553-557.
4. Yokoyama, T., Nakatani, S. and Murakami, A. 2003. A case of Kniest dysplasia with retinal detachment and the mutation analysis. Am. J. Ophthalmol. 136: 1186-1188.
5. Forzano, F., Lituania, M., Viassolo, A., Superti-Furga, V., Wildhardt, G., Zabel, B. and Faravelli, F. 2007. A familial case of achondrogenesis type II caused by a dominant COL2A1 mutation and "patchy" expression in the mosaic father. Am. J. Med. Genet. A. 143A: 2815-2820.
6. Wainwright, H. and Beighton, P. 2008. Visceral manifestations of hypochondrogenesis. Virchows Arch. 453: 203-207.
7. Lo, F.S., Luo, J.D., Lee, Y.J., Shu, S.G., Kuo, M.T. and Chiou, C.C. 2009. High resolution melting analysis for mutation detection for PTPN11 gene: applications of this method for diagnosis of Noonan syndrome. Clin. Chim. Acta 409: 75-77.
8. Benussi, D.G., Costa, P., Zollino, M., Murdolo, M., Petix, V., Carrozzi, M. and Pecile, V. 2009. Trisomy 12p and monosomy 4p: phenotype-genotype correlation. Genet. Test. Mol. Biomarkers 13: 199-204.
9. Online Mendelian Inheritance in Man, OMIM™. 2009. Johns Hopkins University, Baltimore, MD. MIM Number: 605614. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/

CHROMOSOMAL LOCATION

Genetic locus: GCN1L1 (human) mapping to 12q24.23; Gcn1l1 (mouse) mapping to 5 F.

SOURCE

GCN1L1 (L-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of GCN1L1 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-167966 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

GCN1L1 (L-15) is recommended for detection of GCN1L1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

GCN1L1 (L-15) is also recommended for detection of GCN1L1 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for GCN1L1 siRNA (h): sc-95772, GCN1L1 siRNA (m): sc-145362, GCN1L1 shRNA Plasmid (h): sc-95772-SH, GCN1L1 shRNA Plasmid (m): sc-145362-SH, GCN1L1 shRNA (h) Lentiviral Particles: sc-95772-V and GCN1L1 shRNA (m) Lentiviral Particles: sc-145362-V.

Molecular Weight of GCN1L1: 293 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.